CA
NZ
UK
AU
IND
US
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) reported updated interim PYNNACLE Phase 2 ovarian cancer data for rezatapopt showing a 46% ORR among 76 evaluable TP53 Y220C patients and a 10-month median duration of response.
FibroBiologics, Inc. (NASDAQ: FBLG) successfully completed and dispatched the third cGMP lot of its CYWC628 drug product to Australia following rigorous safety and quality evaluations.
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed an sNDA for accelerated approval of XPOVIO in combination with ruxolitinib for myelofibrosis, citing Phase 3 SENTRY results that demonstrated spleen volume reduction and potential disease modification.
Latigo Biotherapeutics (NASDAQ:LTGO) shares rose in pre-market trading after both Goldman Sachs and Guggenheim initiated coverage on the stock with Buy ratings, at price targets of $73 and $50 respectively. Latigo is a clinical-stage biopharmaceutical company headquartered in Thousand Oaks, California, developing non-opioid pain …
Medtronic (NYSE:MDT) shares jumped in pre-market trading after the company reported fiscal first-quarter revenue of $9.8 billion, up 13.7% on both a reported and organic basis, roughly 200 basis points above the midpoint of guidance. Non-GAAPDiluted Earnings per Sharecame in at $1.45, ahead ofWall …
Medtronic (NYSE:MDT) reported first quarter fiscal 2027 revenue of $9.8 billion, an increase of 13.7% both as reported and on an organic basis, coming in roughly 200 basis points above the midpoint of the company's own guidance. The healthcare technology company postedGAAPdiluted earnings per …
PMV Pharma (NASDAQ:PMVP) shares fell sharply in pre-market trading, even as the company reported encouraging interim data from its pivotal ovarian cancer trial, a reaction that appears tied to a same-day financing announcement rather than the clinical update itself. PMV Pharma is a Princeton, …
Shares of SciSparc (NASDAQ:SPRC) fell in pre-market trading even as its majority-owned subsidiary, NeuroThera Labs, reported continued progress in a closely watched pediatric clinical trial, a reaction that runs counter to the update's seemingly positive tone. SciSparc is a Tel Aviv-based clinical-stage specialty pharmaceutical …
Teva (NYSE:TEVA) shares slipped in pre-market trading after the company confirmed it remains in active discussions with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. Teva is a global pharmaceutical company headquartered in Tel Aviv, Israel, …
GSK (NYSE:GSK) shares traded little changed in pre-market activity after the company announced plans to advance FLUm3HA.b-3NA, its mRNA-based seasonal flu vaccine candidate, into a Phase III efficacy trial this month. GSK is a British multinational biopharmaceutical company headquartered in London, developing vaccines and …
Please wait processing your request...